143 related articles for article (PubMed ID: 31054990)
1. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis.
Liu Y; Yu P; Peng X; Huang Q; Ding M; Chen Y; Jin R; Xie J; Zhao C; Li J
J Control Release; 2019 Jun; 304():39-50. PubMed ID: 31054990
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
Bhandari KH; Newa M; Chapman J; Doschak MR
J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin.
Bhandari KH; Newa M; Uludag H; Doschak MR
Int J Pharm; 2010 Jul; 394(1-2):26-34. PubMed ID: 20412845
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
[TBL] [Abstract][Full Text] [Related]
5. Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT).
Kotak DJ; Devarajan PV
Nanomedicine; 2020 Feb; 24():102153. PubMed ID: 31988038
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis.
Bhandari KH; Asghar W; Newa M; Jamali F; Doschak MR
Curr Drug Deliv; 2015; 12(1):98-107. PubMed ID: 25860966
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats.
Wei J; Wang J; Gong Y; Zeng R
Mol Med Rep; 2015 Aug; 12(2):1717-26. PubMed ID: 25891179
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
[TBL] [Abstract][Full Text] [Related]
9. Reversible lipidization for the oral delivery of salmon calcitonin.
Wang J; Chow D; Heiati H; Shen WC
J Control Release; 2003 Mar; 88(3):369-80. PubMed ID: 12644363
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
[TBL] [Abstract][Full Text] [Related]
11. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection.
Youn YS; Kwon MJ; Na DH; Chae SY; Lee S; Lee KC
J Control Release; 2008 Jan; 125(1):68-75. PubMed ID: 18023905
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HPβCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery.
Tewes F; Gobbo OL; Amaro MI; Tajber L; Corrigan OI; Ehrhardt C; Healy AM
Mol Pharm; 2011 Oct; 8(5):1887-98. PubMed ID: 21882837
[TBL] [Abstract][Full Text] [Related]
13. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Sep; 8():5. PubMed ID: 18782439
[TBL] [Abstract][Full Text] [Related]
14. Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate.
Ryan SM; Wang X; Mantovani G; Sayers CT; Haddleton DM; Brayden DJ
J Control Release; 2009 Apr; 135(1):51-9. PubMed ID: 19168100
[TBL] [Abstract][Full Text] [Related]
15. Oral salmon calcitonin--pharmacology in osteoporosis.
Henriksen K; Bay-Jensen AC; Christiansen C; Karsdal MA
Expert Opin Biol Ther; 2010 Nov; 10(11):1617-29. PubMed ID: 20932224
[TBL] [Abstract][Full Text] [Related]
16. Mucoadhesive intestinal devices for oral delivery of salmon calcitonin.
Gupta V; Hwang BH; Lee J; Anselmo AC; Doshi N; Mitragotri S
J Control Release; 2013 Dec; 172(3):753-62. PubMed ID: 24035976
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety.
Cheng W; Lim LY
J Pharm Pharmacol; 2010 Mar; 62(3):296-304. PubMed ID: 20487211
[TBL] [Abstract][Full Text] [Related]
18. Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin.
DeLuca PP; Dani BA
AAPS PharmSci; 2001; 3(4):E27. PubMed ID: 12049490
[TBL] [Abstract][Full Text] [Related]
19. Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide.
Manosroi J; Lohcharoenkal W; Götz F; Werner RG; Manosroi W; Manosroi A
Drug Dev Ind Pharm; 2013 Apr; 39(4):520-5. PubMed ID: 22564052
[TBL] [Abstract][Full Text] [Related]
20. PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights.
Ryan SM; Frías JM; Wang X; Sayers CT; Haddleton DM; Brayden DJ
J Control Release; 2011 Jan; 149(2):126-32. PubMed ID: 20946924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]